Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Southwell, Amber L ^a   Smith, Stephen E P ^b   Davis, Tessa R ^b   Caron, Nicholas S ^a   Villanueva, Erika B ^a   Xie, Yuanyun ^a   Collins, Jennifer A ^a   Li Ye, Min ^a   Sturrock, Aaron ^a   Leavitt, Blair R ^a   Schrum, Adam G ^b   Hayden, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HTT PROTEIN, HUMAN; HUNTINGTIN; HYBRID PROTEIN; NERVE PROTEIN;

ADULT; AGED; ANIMAL; BIOSYNTHESIS; BRAIN; CEREBROSPINAL FLUID; DISEASE MODEL; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; HUNTINGTON CHOREA; IMMUNOBLOTTING; IMMUNOPRECIPITATION; ISOLATION AND PURIFICATION; MALE; METABOLISM; MIDDLE AGED; MOUSE; MUTATION; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MALE; MICE; MIDDLE AGED; MUTATION; NERVE TISSUE PROTEINS; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 84948830873     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12166     Document Type: Article

References (33)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971 (1993).
2. Langbehn, D. R., Hayden, M. R. & Paulsen, J. S. CAG-repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. Am. J. Med. Genet. B: Neuropsych. Genet. 153B, 397 (2010).
3. Wexler, N. S. & Project, T. U. S.-V. C. R. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. PNAS 101, 3498 (2004).
4. Yamamoto, A., Lucas, J. J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57 (2000).
5. Harper, S. Q. et al. From the Cover: RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. PNAS 102, 5820 (2005).
6. Machida, Y. et al. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem. Biophys. Res. Comm. 343, 190 (2006).
7. Rodriguez-Lebron, E., Denovan-Wright, E. M., Nash, K., Lewin, A. S. & Mandel, R. J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 12, 618 (2005).
8. DiFiglia, M. et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. PNAS 104, 17204 (2007).
9. Wang, Y.-L. et al. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci. R. 53, 241 (2005).
10. Franich, N. R. et al. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol. Ther. 16, 947 (2008).
11. Drouet, V. et al. Sustained effects of nonallele-specific huntingtin silencing. Ann. Neurol. 65, 276 (2009).
12. Boudreau, R. L. et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in huntington's disease mice. Mol. Ther. 17, 1053 (2009).
13. Kordasiewicz, Holly B. et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74, 1031 (2012).
14. Khoshnan, A., Southwell, A., Bugg, C., Ko, J. & Patterson, P. in Neurobiology of Huntington's Disease: Applications to Drug Discovery, edited by D. C. Lo & R. E. Hughes (CRC Press, Boca Raton, 2011).
15. Reiner, A. et al. R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice. J. Comp. Neurol. 505, 603 (2007).
16. Carroll, J. B. et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene /Allele-specific silencing of mutant huntingtin. Mol. Ther. 19, 2178 (2011).
17. Southwell, A. L. et al. A fully humanized transgenic mouse model of Huntington disease. Hum. Mol. Genet. 22, 18 (2013).
18. Weiss, A. et al. Single-step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntington's disease. Anal. Biochem. 395, 8 (2009).
19. Macdonald, D. et al. Quantification assays for total and polyglutamine-expanded huntingtin proteins, PLoS ONE 9, e96854 (2014).
20. Schrum, A. G. et al. High-sensitivity detection and quantitative analysis of native protein-protein interactions and multiprotein complexes by flow cytometry. Sci. Signal. 2007, pl2 (2007).
21. Smith, S. E. P. et al. IP-FCM measures physiologic protein-protein interactions modulated by signal transduction and smallmolecule drug inhibition. PLoS ONE 7, e45722 (2012).
22. Ko, J., Ou, S. & Patterson, P. H. New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res. Bull. 56, 319 (2001).
23. Wellington, C. L. et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 22, 7862 (2002).
24. Nasir, J. et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81, 811 (1995).
25. Zeitlin, S., Liu, J. P., Chapman, D. L., Papaioannou, V. E. & Efstratiadis, A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. genet. 11, 155 (1995).
26. Gray, M. et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28, 6182 (2008).
27. Tronche, F. et al. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat. Genet. 23, 99 (1999).
28. Ratovitski, T. et al. Mutant huntingtin n-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J. Biol. Chem. 284, 10855 (2009).
29. Mende-Mueller, L. M., Toneff, T., Hwang, S.-R., Chesselet, M.-F. & Hook, V. Y. H. Tissue-specific proteolysis of huntingtin (htt) in human brain: evidence of enhanced levels of N-and C-terminal htt fragments in Huntington's disease striatum. J. Neurosci. 21, 1830 (2001).
30. Slow, E. J. et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12, 1555 (2003).
31. Southwell, A. L. et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol. Ther. 22, 2093 (2014).
32. Graham, R. K. et al. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J. Neurosci. 29, 2193 (2009).
33. Davis, T. R. & Schrum, A. G. IP-FCM: Immunoprecipitation detected by flow cytometry. J. Vis. Exp. 46, e2066 (2010).